Selected article for: "report case and second phase"

Author: Naneishvili, Tamara; Khalil, Arsalan; O'Leary, Ryan; Prasad, Neeraj
Title: Fulminant myocarditis as an early presentation of SARS-CoV-2
  • Cord-id: fq3eysv2
  • Document date: 2020_9_14
  • ID: fq3eysv2
    Snippet: Myocarditis is well known to be caused by viral infections such as Coxsackie virus group B, human herpes virus 6 and parvovirus B19. However, during the current emerging outbreak of SARS-CoV-2, there have been few case reports describing myocarditis as a possible presentation. In our case report we describe, early cardiac manifestations of SARS-CoV-2 in a UK District General Hospital. A 44-year-old Caucasian woman without any comorbidities presented with SARS-CoV-2 related fulminant myocarditis
    Document: Myocarditis is well known to be caused by viral infections such as Coxsackie virus group B, human herpes virus 6 and parvovirus B19. However, during the current emerging outbreak of SARS-CoV-2, there have been few case reports describing myocarditis as a possible presentation. In our case report we describe, early cardiac manifestations of SARS-CoV-2 in a UK District General Hospital. A 44-year-old Caucasian woman without any comorbidities presented with SARS-CoV-2 related fulminant myocarditis without initial respiratory symptoms. Patient underwent treatment with milrinone and methylprednisolone that showed reduction in myocardial inflammation and significantly improved myocardial contractility. This was then followed by a second phase of SARS-CoV-2 associated pneumonia and renal failure requiring ventilatory support and haemofiltration. Although, not described in the literature, we have found conjunctive use of milrinone and methylprednisolone effective in patient with SARS-CoV-2 fulminant myocarditis.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acute myocarditis: 1
    • ace inhibitor and admission time: 1
    • ace inhibitor and lung inflammatory: 1, 2
    • acid base balance and admission day: 1
    • acute coronary syndrome and admission day: 1, 2, 3, 4
    • acute coronary syndrome and admission time: 1, 2, 3, 4
    • acute coronary syndrome and loading dose: 1, 2
    • acute coronary syndrome and lung inflammatory: 1, 2
    • acute fulminant myocarditis and admission day: 1
    • acute myocarditis and admission day: 1, 2
    • acute myocarditis and admission time: 1
    • acute myocarditis and low suspicion: 1, 2
    • acute myocarditis and lung inflammatory: 1, 2
    • admission day and loading dose: 1, 2
    • admission day and low suspicion: 1, 2
    • admission day and lung inflammatory: 1, 2, 3, 4
    • admission time and loading dose: 1
    • admission time and low suspicion: 1
    • admission time and lung inflammatory: 1